title: NMDA-dependent modulation of CA1 local circuit inhibition.
abstract: Whole-cell and extracellular recording techniques were used to examine local circuit inhibition in the CA1 region of the rat hippocampus in vitro. Activation, primarily of the recurrent inhibitory circuit by alvear stimulation, elicited an IPSP in pyramidal neurons that was dependent, in part, on NMDA receptor activation. Application of a tetanizing stimulus to the alveus evoked long-term potentiation (LTP) of the intracellularly recorded recurrent IPSPs. This LTP also was NMDA-dependent and was more sensitive to blockade by the NMDA antagonists 2-amino-5-phosphonovalerate (APV) and N-acetyl-aspartyl-glutamate, than the excitatory LTP produced by Schaffer collateral stimulation. With regard to APV, the sensitivity of inhibitory LTP was an order of magnitude greater. A biophysical simulation of hippocampal CA1 circuitry was used in a model of learned pattern recognition that included LTP in both excitatory and inhibitory recurrent circuits. In this model, selective blockade of inhibitory LTP produced aberrant spread of lateral excitation, resulting in confusion of normally distinguishable patterns of neuronal activity. Consideration is given to the possibility that selective disruption of NMDA-dependent modulation of local circuit inhibition may serve as a model for some aspects of dysfunction associated with NMDA-antagonist exposure and schizophrenia.
authors.affiliation: Department of Psychiatry, Harvard University, Cambridge, Massachusetts 02138, USA.
authors.forename: H C
authors.initials: HC
authors.lastname: Grunze
authors.forename: D G
authors.initials: DG
authors.lastname: Rainnie
authors.forename: M E
authors.initials: ME
authors.lastname: Hasselmo
authors.forename: E
authors.initials: E
authors.lastname: Barkai
authors.forename: E F
authors.initials: EF
authors.lastname: Hearn
authors.forename: R W
authors.initials: RW
authors.lastname: McCarley
authors.forename: R W
authors.initials: RW
authors.lastname: Greene
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000818:Animals; D004151:Dipeptides / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D004594:Electrophysiology; D005260:Female; D006624:Hippocampus / Q000502:physiology*; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D017774:Long-Term Potentiation / Q000187:drug effects*; D008297:Male; D008564:Membrane Potentials / Q000502:physiology; D016202:N-Methylaspartate / Q000494:pharmacology*; D009412:Nerve Fibers / Q000502:physiology; D009433:Neural Inhibition / Q000502:physiology; D010622:Phencyclidine / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012680:Sensitivity and Specificity; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology
chemical_list: D004151:Dipeptides; D006634:Histamine H1 Antagonists; C027172:isospaglumic acid; D016202:N-Methylaspartate; D015763:2-Amino-5-phosphonovalerate; D010622:Phencyclidine